The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The HERBY study: A phase II open label, randomized, multicenter, comparative study of bevacizumab (Bv)-based therapy in pediatric patients with newly diagnosed supratentorial high-grade glioma (HGG).
Jacques Grill
Consultant or Advisory Role - Roche
Honoraria - Roche
Darren R Hargrave
Consultant or Advisory Role - Roche
Expert Testimony - Roche (U)
Pascale Varlet
Consultant or Advisory Role - Roche
Research Funding - Roche
Expert Testimony - Roche
Tim Jaspan
Consultant or Advisory Role - Roche (U)
Chris Jones
Consultant or Advisory Role - Roche (U)
Research Funding - Roche/Genentech
Other Remuneration - Roche/Genentech
Maura Massimino
Consultant or Advisory Role - Roche
Honoraria - Roche
Adela Cañete
Consultant or Advisory Role - Roche
Amedeo A. Azizi
Consultant or Advisory Role - Roche
Marie-Cécile Le Deley
No relevant relationships to disclose
Frank Saran
Consultant or Advisory Role - Roche
Paul Morgan
Consultant or Advisory Role - Roche (U)
Gudrun Zahlmann
Employment or Leadership Position - Roche; Roche
Stock Ownership - Roche; Roche
Louis Viviers
No relevant relationships to disclose
Jeanette Bachir
No relevant relationships to disclose
Aijing Shang
Employment or Leadership Position - Roche
Stock Ownership - Roche
Raphael F. Rousseau
Employment or Leadership Position - Roche
Stock Ownership - Roche
Gilles Vassal
Research Funding - Roche